Close Menu
Home » Editas Medicine to Provide Broad Institute With up to $125M in CRISPR Funding

Editas Medicine to Provide Broad Institute With up to $125M in CRISPR Funding

Jun 11, 2018
|
staff reporter

NEW YORK (GenomeWeb) — CRISPR-based therapeutics developer Editas Medicine has agreed to provide up to $125 million in research funding to the Broad Institute in exchange for the exclusive right to be the first to negotiate for licenses to genome-editing inventions that arise from the sponsored research.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Hope, But Cost Worries

Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.

Cleared the Committee

The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.

One Gene to Shape the Face

One gene regulates hundreds of others to influence facial development, according to New Scientist.

Nature Studies Review Resources for Single-Cell Analysis, Examine ALS Exomes, More

In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.

What's Popular?

In Business News

  1. Illumina, PacBio Dispute UK Regulator's Finding That Merger Would Weaken Competition

  2. Ambry Genetics, Caris Life Sciences Partner on Cancer Genetic Testing

  3. Illumina, ArcherDx Expand Partnership on NGS IVD Tests

  4. Veracyte Exclusively Licenses NanoString Diagnostic Platform for Up to $60M

  5. Alzheimer's Drug Discovery Foundation Awards $5.5M in Grants for Diagnostic Development

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.